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Colorectal cancer (CRC) is one of the most common malignancies, and it is the second leading cause of death from cancer in the United States. It is estimated that 135,430 new cases developed and 50,260 deaths occurred in 2017 1 . Identifying lymph node (LN) metastases is one of the most important steps for staging rectal cancer because it helps guide therapeutic decisions and determine the long-term outcome 2, 3 . Clinically, LN size, measured by computed tomography (CT) or magnetic resonance imaging (MRI), is the most common criteria used to determine pathologic LNs. An LN with greater than 1 cm short-axis diameter is considered pathologic; however, the upper limit of benign LNs differs depending on the anatomic location and tumor type 4, 5 . Furthermore, nodal metastases can occur in normal-sized LNs less than 1 cm 6 . Thus, nodal staging based on LN size shows low sensitivity in identifying small metastatic LNs in patients with rectal cancer using conventional imaging modalities 7, 8 . Positron emission tomography (PET)/CT with [ 
]FDG) has been widely used for staging, restaging, and detection of recurrent disease in rectal cancer [9] [10] [11] . Although the specificity of [ 18 F]FDG PET/CT in detecting nodal metastases has been known to be excellent, its sensitivity is relatively low 12 [16] [17] [18] ; however, no studies have attempted to develop a prediction model for LN metastases status in rectal cancer using both MTV of the primary tumor (T_MTV) and [ 
Results patient Characteristics.
A total of 166 patients with rectal cancer who received curative surgical resection were retrospectively analyzed. The characteristics of the enrolled patients (mean age, 66.7 ± 10.6 years) and the associations with LN metastases are listed in Table 1 . LN metastases were confirmed histologically in 68 patients (41%), and 98 patients (59%) presented with no LN metastases. Although the majority of patients were diagnosed with 7th American Joint Committee on Cancer (AJCC) stage I-III cancer, two patients with pathologic stage Tis were classified as stage 0, and one patient with distant metastasis was classified as stage IV. The stage IV patient had 6 nodal metastases (N2a) and underwent a low anterior resection of a single hepatic metastasis and left hepatectomy. Pathologic stages according to the 7th AJCC and PET parameters, such as SUVmax of primary tumor (T_SUVmax), T_MTV, and N_SUVmax, were significantly different between the two groups; however, no significant differences were found with respect to pre-operative carcinoembryonic antigen (CEA), pathologic tumor size, and histologic grade. Thirty-nine of the 166 patients (23.5%) showed positive nodal uptake by [ 18 F]FDG PET/CT findings. Of these 39 patients, 33 (84.6%) had histologically confirmed LN metastases. On the contrary, LN metastases were confirmed histologically in 35 (27.6%) of the 127 patients with negative nodal FDG uptake. 
Uni-and Multivariate Analyses.
Univariate logistic regression analysis revealed that T_SUVmax, T_MTV, and N_SUVmax were significantly associated with LN metastases (Table 2 ). In the multivariate analysis, both T_MTV (odds ratio [OR], 1.022; 95% confidence interval [CI], 1.001-1.043; P = 0.038) and N_SUVmax (OR, 2.181; 95% CI, 1.523-3.125; P < 0.001) were found to be significant predictive factors; otherwise, T_SUVmax was justifiably removed from the stepwise model. These two independent parameters were used to construct a nomogram for risk prediction of LN metastasis (Fig. 1) . To use the nomogram, the points for each parameter should be determined by drawing a vertical line from the exact value of the variables to the points row. Then, total points are calculated by arithmetic sum. Finally, the individual predictive probability of LN metastasis can be obtained by drawing a vertical line from the total points row to the probability of LN metastasis row.
Comparison of LN Metastasis prediction performance. When LN metastases prediction performance was analyzed using receiver operating characteristic (ROC) curve analysis, the area under the curve (AUC) was 0.698 for T_MTV (Standard Error [SE], 0.040; 95% CI, 0.622-0.767) and 0.720 for N_SUVmax (SE, 0.033; 95% CI, 0.646-0.787). We were able to build an improved prediction model that combined T_MTV and N_SUVmax. The c-statistics of combined model was 0.806 (SE, 0.034; 95% CI, 0.737-0.863), and it showed significant improvement in accuracy of LN metastases prediction compared to T_MTV (P = 0.0002) or N_SUVmax (P = 0.0008) alone (Fig. 2) . However, no significant difference was found between T_MTV and N_SUVmax (P = 0.64). Table 2 . Uni-and multivariate logistic regression analyses for regional lymph node metastases. OR = Odds Ratio; CI = Confidence Interval; CEA = Carcinoembryonic Antigen; PET/CT = Positron Emission Tomography/Computed Tomography; SUVmax = maximum standardized uptake value; MTV = Metabolic Tumor Volume.
Figure 1.
Nomogram for predicting the probability of regional LN metastasis using pretreatment [
18 F]FDG PET/CT parameters. First, the number of points for each parameter -T_MTV and N_SUVmax -should be determined by drawing a vertical line from the exact value of variables to the points row. Subsequently, total points can be obtained by sum of two variables. The individual predictive probability of regional LN metastasis can be calculated by drawing a vertical line from the total points row to the probability of regional LN metastasis. LN = lymph node; [ 
Discussion
In the current study, we assessed the diagnostic value of metabolic parameters measured by [ 18 F]FDG PET/CT for the prediction of LN metastases in patients with rectal cancer. Our results demonstrated that nodal [ 18 F]FDG uptake findings were highly specific for LN metastases status, but it had a limitation due to its relatively low sensitivity. To overcome this limitation, we used metabolic parameters such as T_MTV and N_SUVmax for precise diagnosis of LN metastases. T_MTV and N_SUVmax are independent predictive factors for LN metastases in patients with rectal cancer. Moreover, the combination of both parameters significantly improved LN metastases prediction beyond each independent parameter alone (Fig. 3) .
The sensitivity of [
18 F]FDG PET/CT was found to be relatively low (48.5%), although the specificity was high (93.9%). This finding is similar to that in previous studies, which showed poor sensitivity for detecting LN metastases 12, 19 . In this study, we excluded the patients who had received neoadjuvant treatment, since any treatment before surgical resection could affect the histopathologic results, including the initial LN status. If these advanced rectal cancer patients who underwent neoadjuvant chemotherapy were included in the present study, the LN detectability of [ 12 . Concordantly, N_SUVmax was an independent prognostic factor for LN metastases in this study. We, therefore, have incorporated N_SUVmax as well as T_MTV for LN metastases prediction. Additionally, the combination of T_MTV and N_SUVmax could improve LN metastases prediction in patients with rectal cancer.
The present study also suggested that T_MTV could be a useful complementary predictive factor itself for LN metastases. Recently, several studies have shown that volumetric parameters measured by [ 18 F]FDG PET/CT are useful for the evaluation of therapeutic response or prognostication in a variety of malignancies [21] [22] [23] [24] [25] ; T_MTV can be used as a predictive factor for LN metastases in lung, endometrial, and uterine cervical cancers 18, 26, 27 . Our result is consistent with previous studies in that T_MTV obtained by [ 18 F]FDG PET/CT could be an effective marker of total tumor burden and may reflect the aggressiveness of cancer associated with LN metastases. A previous meta-analysis identified numerous histopathological factors that may be correlated with LN metastases in primary CRC 28 . However, no single histopathological feature reliably predicted LN metastases, and these factors can be evaluated only after surgery. Considering the feasibility of [ 18 F]FDG PET/CT in the pre-operative setting www.nature.com/scientificreports www.nature.com/scientificreports/ of rectal cancer, [ 18 F]FDG PET/CT could be used as a non-invasive and pre-operative diagnostic tool for assessment of LN status in patients with rectal cancer.
The status of LN metastases is the most important prognostic factor in patients with rectal cancer. The five-year survival rate for patients with node-negative rectal cancer is 70-80%, whereas it is only 30-60% in node-positive rectal cancer. Accordingly, LN status assessment remains one of main factors used in determining neoadjuvant treatment in patients with rectal cancer 29 . Although [ 18 F]FDG PET/CT can affect staging and treatment strategies, the current evidence is not considered strong enough to recommend the routine use of [
18 F]FDG PET/CT for initial staging 30, 31 . The main reason for this is the lack of additional diagnostic value of [ 18 F]FDG PET/CT. In that regard, the improved diagnostic performance of the combination model for predicting LN metastases maybe helpful in selecting patients who should receive neoadjuvant treatment. Additionally, [ 18 F]FDG PET/CT might be helpful in determining risk-adapted treatment and long-term patient outcome by providing more accurate information regarding LN status. A multi-institutional, large prospective study is necessary for the combination model of T_MTV and N_SUVmax on pretreatment [ 18 F]FDG PET/CT to be accepted as a significant prognostic factor in patients with rectal cancer.
This study had a few limitations. First, the single-center retrospective design of this study might be subject to selection bias. Further studies are needed to validate the results of the present study. Second, physiologic [ 18 F] FDG uptake in the gastrointestinal tract may cause overestimation of T_MTV. Therefore, we adopted an absolute SUV threshold of 2.5 for MTV measurement, which was a widely used cutoff value in several previous studies and could reduce inter-and intra-observer variation in delineation of tumor volume using a software-assisted automatic method 21, 32 . Lastly, we did not correct for a partial volume effect, which may have underestimated the value of SUVmax; this is because partial volume correction is generally too complex to use in daily clinical practice. New and feasible partial volume correction methods would be helpful in achieving precise quantification and clinical application 33, 34 . Despite these limitations, we have shown that the combination of T_MTV and N_SUVmax could be an attractive strategy to further improve the diagnostic performance of [
18 F]FDG PET/CT for LN metastases in patients with rectal cancer.
In conclusion, T_MTV and N_SUVmax were independent prognostic factors for the prediction LN metastases in rectal cancer patients. Furthermore, our prediction model using T_MTV and N_SUVmax could provide a more precise prediction of LN metastases. The use of N_SUVmax in combination with T_MTV on preoperative [ 18 F]FDG PET/CT were evaluated retrospectively. Of these, patients who received neoadjuvant chemoradiotherapy (n = 96), endoscopic tumor removal prior to surgery (n = 24), or long delayed interval over than 1 month between [
18 F]FDG PET/CT and surgery (n = 10) were excluded. A total of 166 patients were enrolled in this study. Surgery (160 patients with anterior resection, 4 with abdominoperineal resection, 1 with Hartmann's operation, and 1 with total proctocolectomy) was performed by experienced colorectal surgeons, which included total mesorectal excision and at least 14 LNs were harvested. All of the patients were pathologically staged according to the 7th AJCC staging system 35 . The Institutional Review Board of Keimyung University Dongsan Medical Center approved this retrospective study and waived the requirement to obtain informed consent (2018-04-008 www.nature.com/scientificreports www.nature.com/scientificreports/ acquired 60 minutes after 5.5 MBq/kg (Discovery STe) or 4.0 MBq/kg (Biograph mCT) of FDG was administered intravenously. First, low-dose CT scan (Discovery STe; peak voltage of 120 kVp and slice thickness of 3.75 mm, Biograph mCT; peak voltage of 120 kVp and slice thickness of 3 mm) was acquired for attenuation correction. Immediately following the CT scan, PET scan was obtained with an acquisition time of 3 min per bed position for Discovery STe and 1.5 min per bed position for Biograph mCT in 3D mode. PET images were reconstructed using an ordered-subset expectation maximum iterative reconstruction algorithm.
Image Analysis. Statistical Analysis. Numeric data are expressed as mean ± standard deviation. Univariate and multivariate logistic regression analyses were performed to identify significant variables associated with LN metastasis. The prediction model of LN metastases, with the combination of significant parameters, was developed by using multivariable logistic regression modeling. A nomogram was established to be a graphic representation of the LN metastases prediction model based on the result of multivariate logistic regression analysis. The additional value of risk prediction for LN metastases was evaluated using c-statistics, and DeLong method was used to compare the difference between the AUC 36 . Statistical analyses were performed using MedCalc for Windows, version 18.2.1 (MedCalc Software, Ostend, Belgium) and R version 3.4.3 software (http://www.r-project.org, R Foundation for Statistical Computing, Vienna, Austria). All P values < 0.05 were considered statistically significant.
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